Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard–Soulier syndrome

Ozelo, Margareth Castro; Svirin, Pavel; Larina, Lubov
December 2005
Annals of Hematology;Dec2005, Vol. 84 Issue 12, p816
Academic Journal
Bernard–Soulier syndrome (BSS) is a rare congenital platelet disorder characterized by defective platelet adhesion and manifested by spontaneous and often profuse bleeding. Recombinant factor VIIa (rFVIIa) is a haemostatic agent licensed for the treatment of bleeding episodes in patients with haemophilia and inhibitors, which may represent a low-risk alternative to existing therapies in the management of patients with BSS. Here, we describe the use of rFVIIa for the treatment of three severe bleeding episodes in two patients with BSS. Data were extracted by automated searching of the international, Internet-based registry . Patient 1, a 24-year-old woman, was admitted with severe epistaxis and hypotension. The diagnosis of BSS was confirmed by macrothrombocytopenia, absence of ristocetin-induced platelet agglutination (RIPA) and absence of glycoprotein (GP) Ibα and IX on the platelet surface. Epsilon aminocaproic acid (EACA; two 50-mg/kg doses), packed red blood cells (PRBCs, 2 U) and platelets (30 U) failed to control the bleeding and, after 13 h, three bolus doses of rFVIIa (90 μg/kg body weight) and a third dose of EACA were administered; bleeding stopped after the third dose of rFVIIa. Patient 2, a 15-year-old girl, initially presented with severe menorrhagia. A lack of RIPA and severe deficiency of GPIbα on the platelet surface confirmed the diagnosis of BSS. EACA and fresh-frozen plasma did not control the haemorrhage, but two bolus doses of rFVIIa (98 μg/kg body weight) resulted in a marked decrease in bleeding. On second admission, patient 2 had severe epistaxis and mild menorrhagia. Two rFVIIa doses (98 and 122.5 μg/kg body weight) were given, and the bleeding stopped. No adverse events were reported in these cases. These three admissions highlight the potential of rFVIIa for the treatment of severe bleeds in patients with BSS.


Related Articles

  • Pseudothrombocytopenia: A Rare Phenomenon. Makris, Pantelis E.; Foka, Zoi; Gerotziafas, Grigoris T.; Kioumi, Anna; Pithara, Eleutheria // Clinical & Applied Thrombosis/Hemostasis;Jul1998, Vol. 4 Issue 3, p167 

    Thrombocytopenia is a serious situation that causes anxiety in doctors due to its relationship with serious hemorrhagic manifestations. Pseudothrombocytopenia, however, is a situation without clinical interest because it is an in vitro decrease in platelet count. Pseudothrombocytopenia is...

  • Control of Bleeding Caused by Thrombocytopenia Associated With Hematologic Malignancy: An Audit of the Clinical Use of Recombinant Activated Factor VII. Brenner, Benjamin; Hoffman, Ron; Balashov, Dmitriy; Shutluko, Elena; Čulić, Srđana; Nizamoutdinova, Elena // Clinical & Applied Thrombosis/Hemostasis;Oct2005, Vol. 11 Issue 4, p401 

    This paper presents an analysis of 24 cases in which recombinant factor Vila (rFVIIa) was used in the management of hemorrhage in patients with thrombocytopenia associated with hematologic malignancies. This is the largest case aggregation to date and focuses on preliminary experience in the...


    Sex-linked immunodeficiency with thrombocytopenia and eczema, described by various scientists, is a devastating disease that has posed a fascinating enigma from both hematologic and immunologic points of view. Affected boys usually die in early childhood from infections, hemorrhage and severe...

  • PREGNANCY IN A PATIENT OF GLANZMANN'S THROMASTHENIA. Malhotra, Neena; Chanana, Charu; Deka, Deepika // Indian Journal of Medical Sciences;Mar2006, Vol. 60 Issue 3, p111 

    Glanzmann's thrombasthenia is a congenitally acquired platelet disorder with an autosomal recessive mode of inheritance. Though, quantitatively normal, the aggregation ability of platelets is reduced in this condition. Pregnancy and delivery are rare in these patients and have been associated...

  • Molecular Dynamics Analysis of a Novel β3 Pro189Ser Mutation in a Patient with Glanzmann Thrombasthenia Differentially Affecting αIIbβ3 and αvβ3 Expression. Laguerre, Michel; Sabi, Essa; Daly, Martina; Stockley, Jacqueline; Nurden, Paquita; Pillois, Xavier; Nurden, Alan T. // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Mutations in ITGA2B and ITGB3 cause Glanzmann thrombasthenia, an inherited bleeding disorder in which platelets fail to aggregate when stimulated. Whereas an absence of expression or qualitative defects of αIIbβ3 mainly affect platelets and megakaryocytes, αvβ3 has a widespread...

  • Oozing and Bruising Due to Abnormal Platelet Function (Thrombocytopathia). Zucker, Stanley; Mielke, Harold; Durocher, John R.; Crosby, William H. // Annals of Internal Medicine;May72, Vol. 76 Issue 5, p725 

    Presents a study that described the condition of patients with mild bleeding disorders caused by abnormalities of platelet function or thrombocytopathia. Characteristics of the syndrome; Factors that contribute to the presence of bruises; Patients and methods; Results of the study.

  • Do we know when to treat neonatal thrombocytopaenia? Venkatesh, Vidheya; Curley, Anna E.; Clarke, Paul; Watts, Timothy; Stanworth, Simon J. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Sep2013, Vol. 98 Issue 5, pF380 

    The article offers information related to thrombocytopaenia, which is a condition of relative decrease of platelets in blood. It informs that the thrombocytopaenia is affecting around 25 percent of all neonates admitted to neonatal intensive care units in the U.S. It mentions that platelet...

  • Between remission and cure: patients, practitioners and the transformation of leukaemia in the late twentieth century. Barnes, Emm // Chronic Illness;Dec2007, Vol. 3 Issue 4, p253 

    Objectives: During the course of the 1960s and 1970s, acute leukaemia in childhood ceased to be invariably fatal and was recategorized as curable. The meaning of cure in this case, however, was problematic, as it was impossible for physicians to be certain that cancer would not return. This...

  • Bone marrow biopsy morbidity: review of 2003. Bain, B. J. // Journal of Clinical Pathology;Apr2005, Vol. 58 Issue 4, p406 

    Background: Although some hazards are recognised, in general, bone morrow aspiration and trephine biopsy are thought to be safe procedures. Until recently, no attempt hod been made to quantify any attendant risks. For this reason, documentation of adverse events was begun in 2001, under the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics